Research Status of Zexietang
10.13422/j.cnki.syfjx.20210648
- VernacularTitle:泽泻汤的研究现状
- Author:
Lin YAN
1
;
Xin-jian LI
2
;
Bing-bing ZHANG
2
;
Ze-min OU
2
;
Yan-jing WANG
3
;
Yao ZHANG
3
;
De-wen LIU
2
;
Zhen-shan MA
2
;
Jin-yu WANG
2
;
Yan TONG
2
Author Information
1. Jiangxi University of Chinese Medicine，Nanchang 330004，China
2. Institute of Chinese Materia Medica，China Academy of Chinese Medical Sciences，Beijing 100700，China
3. Tianjin University of Traditional Chinese Medicine，Tianjin 301617，China
- Publication Type:Research Article
- Keywords:
Zexietang;
chemical composition;
pharmacological effect;
clinical application;
famous classical formulas;
diuresis;
hypotensive
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2021;27(16):191-197
- CountryChina
- Language:Chinese
-
Abstract:
Zexietang is derived from Jingui Yaolue （《金匮要略》）， which is composed of Alismatis Rhizoma and Atractylodis Macrocephalae Rhizoma， and has the effect of inducing diuresis and invigorating the spleen to produce water. Compared with western medicine in the treatment of related diseases， Zexietang can not only improve the curative effect， but also reduce the occurrence of adverse reactions， so as to achieve long-term stable administration. The authors sorted out and analyzed the chemical composition， pharmacological effect and clinical application of Zexietang in recent years. It was found that the main active components of Zexietang were alismol A and B， 23-acetyl-alismol B and C， atractylenolides （atractylenolide Ⅰ， Ⅱ， Ⅲ） and polysaccharides. Pharmacological experiments showed that they had diuretic， hypolipidemic， anti-inflammatory and others. And it can be used in the treatment of hypertension， hyperlipidemia， vertigo， cerebral vascular insufficiency and other diseases combined with other Chinese materia medica， and the curative effect is obvious. By summarizing the research status of Zexietang in recent years， its active components and pharmacological mechanism can be further clarified， which provides the basis for the clinical application of Zexietang and guides the direction of its further research.
